#United States #Durham, North Carolina #Prostate Cancer #Levee Medical #Voro Urologic

Levee Medical® Secures Pivotal U.S. Patent for Voro® Urologic Scaffold

Levee Medical®, a prominent player in the medical device sector, recently celebrated a significant milestone with the issuance of U.S. Patent No. 12,324,586. This patent, granted by the United States Patent and Trademark Office on June 10, 2025, covers the innovative Voro® Urologic Scaffold, which is designed to enhance patient outcomes post-prostate cancer surgery. This revolutionary device specifically addresses issues related to stress urinary incontinence, a common complication for men following such medical procedures.

The issuance of this patent represents a substantial step forward in Levee Medical's commitment to improving the lives of prostate cancer patients. Bruce Choi, the Founder and Chairman of Levee Medical, expressed his enthusiasm for this advancement, emphasizing that patent protections are critical for safeguarding the unique technology and procedures involved with the Voro® device. The scaffold has been meticulously engineered to provide support for the bladder neck and to restore urethra length—two anatomical considerations vital for fostering a quicker return to urinary control after surgical interventions.

With this latest protection, Levee Medical now possesses four issued patents and has twelve additional applications in the pipeline, targeting key global markets including the United States, Europe, China, and Japan. This comprehensive strategy not only solidifies Levee's intellectual property stance but also fosters a stronger competitive edge in the urologic device marketplace.

Driving the ARID II Study Forward

In conjunction with the patent issuance, Levee Medical is witnessing strong momentum in its landmark ARID II clinical trial, which evaluates the effectiveness and safety of the Voro® Urologic Scaffold in patients undergoing robotic-assisted radical prostatectomy. This pivotal study is gaining traction, highlighted by successful site activations and increased patient enrollment, signifying a growing interest from both researchers and medical institutions to engage in this innovative research. Joh Hopkins Medicine has recently collaborated with Levee Medical under the guidance of Dr. Arvin George, the national Principal Investigator, further bolstering the credibility and outreach of the ARID II trial.

Dr. George has voiced confidence in the potential impact of this trial, noting that emerging data could inform strategies to enhance recovery and possibly minimize incontinence following radical prostatectomy. The excitement surrounding ARID II stems not just from its objectives to reduce postoperative complications but also from its potential to provide groundbreaking insights into the recovery process of urinary control post-surgery.

Looking Ahead

As Levee Medical prepares to release the Voro Urologic Scaffold to the market, the company remains steadfast in its mission to create better surgical outcomes for prostate cancer patients. The Voro device, currently limited to investigational use, marks a pivotal moment in the company's journey toward commercialization. While it is not yet approved for commercial use, the data derived from the ARID II trial will be instrumental in showcasing its efficacy and paving the way for approval in various markets.

In conclusion, the issuance of the foundational patent for the Voro® Urologic Scaffold not only enhances Levee Medical's intellectual property framework but also positions the firm strategically within the competitive landscape of medical device innovation. With unwavering commitment to reducing complications associated with prostate cancer surgery, Levee aims to remain at the forefront of advancements in urologic solutions. For further information, visit Levee Medical's website.